T-cell dysfunction in natural killer/T-cell lymphoma

References

• Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10(1):85. doi:10.1186/s13045-017-0452-9.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Miyazaki K. Current treatment approaches for NK/T-cell lymphoma. J Clin Exp Hematop. 2017;57(3):98–10. doi:10.3960/jslrt.17018.
   PubMedGoogle Scholar
• Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997–5005. doi:10.1182/blood-2013-01-453233.
   PubMed Web of Science ®Google Scholar
• Cai Q, Chen K, Young KH. Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders. Experimental & Molecular Medicine. 2015;47(1):e133. doi:10.1038/emm.2014.105.
   PubMedGoogle Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17. doi:10.3389/fcell.2020.00017.
   PubMed Web of Science ®Google Scholar
• Xia A, Zhang Y, Xu J, Yin T, Lu XJ. T cell dysfunction in cancer immunity and immunotherapy. Front Immunol. 2019;10:1719. doi:10.3389/fimmu.2019.01719.
   PubMed Web of Science ®Google Scholar
• Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, Pantaleo G. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292(1):149–163. doi:10.1111/imr.12823.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death & Disease. 2015;6(6):e1792. doi:10.1038/cddis.2015.162.
   PubMed Web of Science ®Google Scholar
• Gao Z, Feng Y, Xu J, Liang J. T-cell exhaustion in immune-mediated inflammatory diseases: new implications for immunotherapy. Front Immunol. 2022;13:977394. doi:10.3389/fimmu.2022.977394.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani, R, Ghielmini , M, Salles , GA, Zelenetz , AD. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Shao Q, Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):27–35. doi:10.1038/s41423-019-0344-8.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ. Tumor microenvironment, metabolism, and immunotherapy. N Engl J Med. 2020;382(9):869–871. doi:10.1056/NEJMcibr1914890.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens , LM, Gabrilovich , DI, Ostrand-Rosenberg , S, Hedrick , CC. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547–562. doi:10.1016/j.ccell.2018.03.012.
   PubMed Web of Science ®Google Scholar
• Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris , RL, Delgoffe , GM. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45(2):374–388. doi:10.1016/j.immuni.2016.07.009.
   PubMed Web of Science ®Google Scholar
• Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay , AG, Gribben , JG. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612–1621. doi:10.1182/blood-2012-09-457531.
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad , A, Frutos , C, Galeano , S, Hamad , N. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045–1053. doi:10.3324/haematol.2021.279189.
   PubMed Web of Science ®Google Scholar
• Roussel M, Le KS, Granier C, Llamas Gutierrez F, Foucher E, Le Gallou S, Pangault C, Xerri L, Launay V, Lamy T, et al. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Adv. 2021;5(7):1816–1829. doi:10.1182/bloodadvances.2020003080.
   PubMed Web of Science ®Google Scholar
• Liu L, Chang YJ, Xu LP, Zhang XH, Wang Y, Liu KY, Huang X-J. T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clin Immunol. 2018;190:32–40. doi:10.1016/j.clim.2018.02.009.
   PubMed Web of Science ®Google Scholar
• Ozkazanc D, Yoyen-Ermis D, Tavukcuoglu E, Buyukasik Y, Esendagli G. Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells. Immunology. 2016;149(4):460–471. doi:10.1111/imm.12665.
   PubMed Web of Science ®Google Scholar
• Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 2016;22(8):1856–1864. doi:10.1158/1078-0432.CCR-15-1849.
   PubMed Web of Science ®Google Scholar
• Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci. 2021;277:119627. doi:10.1016/j.lfs.2021.119627.
   PubMed Web of Science ®Google Scholar
• Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116. doi:10.1186/s12943-020-01234-1.
   PubMed Web of Science ®Google Scholar
• Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, et al. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20(6):724–735. doi:10.1038/s41590-019-0346-9.
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119. doi:10.1038/s41590-017-0022-x.
   PubMed Web of Science ®Google Scholar
• Budhwar S, Verma P, Verma R, Rai S, Singh K. The yin and yang of myeloid derived suppressor cells. Front Immunol. 2018;9:2776. doi:10.3389/fimmu.2018.02776.
   PubMed Web of Science ®Google Scholar
• Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002;195(7):893–905. doi:10.1084/jem.20011692.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798–808. doi:10.1200/JCO.2013.51.5304.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother (1991). 2004;27(4):317–327. doi:10.1097/00002371-200407000-00008.
   Web of Science ®Google Scholar
• Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu M-F, Liu H, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother (1991). 2010;33(9):983–990. doi:10.1097/CJI.0b013e3181f3cbf4.
   PubMed Web of Science ®Google Scholar
• Li J, Zeng XH, Mo HY, Rolén U, Gao YF, Zhang XS, Chen Q-Y, Zhang L, Zeng M-S, Li M-Z, et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLos One. 2007;2(11):e1122. doi:10.1371/journal.pone.0001122.
   PubMed Web of Science ®Google Scholar
• Catakovic K, Klieser E, Neureiter D, Geisberger R. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal. 2017;15(1):1. doi:10.1186/s12964-016-0160-z.
   PubMed Web of Science ®Google Scholar
• Lambert SL, Martinez OM. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol. 2007;179(12):8225–8234. doi:10.4049/jimmunol.179.12.8225.
   PubMed Web of Science ®Google Scholar
• Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, Huang H-Q, Jiang W-Q, Zhang Y-J, Wang L. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016;9(1):109. doi:10.1186/s13045-016-0341-7.
   PubMedGoogle Scholar
• Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ, Bloemena E, Middeldorp JM. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol. 2000;165(2):663–670. doi:10.4049/jimmunol.165.2.663.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong P-L, Loong F, Au-Yeung R, Iqbal J, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437–2442. doi:10.1182/blood-2016-12-756841.
   PubMed Web of Science ®Google Scholar
• Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang , X, Chang , Y, Sun , Z, Yu , H. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15. doi:10.1186/s13045-018-0559-7.
   PubMed Web of Science ®Google Scholar
• Cai J, Liu P, Huang H, Li Y, Ma S, Zhou H, Tian X, Zhang Y, Gao Y, Xia Y, et al. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduct Target Ther. 2020;5(1):289. doi:10.1038/s41392-020-00331-3.
   PubMed Web of Science ®Google Scholar
• Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326–336. doi:10.1038/s41590-019-0312-6.
   PubMed Web of Science ®Google Scholar
• Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan , Q, Hale , JS, Lee , J, Nasti , TH. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417–421. doi:10.1038/nature19330.
   PubMed Web of Science ®Google Scholar
• Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff , EK, Robertson , EJ, Lauer , GM, Reiner , SL. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012;338(6111):1220–1225. doi:10.1126/science.1229620.
   PubMed Web of Science ®Google Scholar